Drug Profile
HQK 1001
Alternative Names: HQK-1001; ST-20Latest Information Update: 29 Jul 2015
Price :
$50
*
At a glance
- Originator HemaQuest Pharmaceuticals
- Class Antianaemics; Small molecules; Volatile fatty acids
- Mechanism of Action Erythropoiesis stimulants; Fetal haemoglobin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Beta-thalassaemia; Sickle cell anaemia
Most Recent Events
- 10 Jun 2013 HemaQuest completes enrolment in its phase IIb trial for Sickle cell anaemia (twice-daily dosing) in USA, Canada, Jamaica, Egypt & Lebanon (NCT01601340)
- 31 Jan 2013 Boston University & HemaQuest complete a phase II trial in Beta-thalassaemia in Lebanon (NCT01642758)
- 31 Jul 2012 Phase-II clinical trials in Sickle cell anaemia in Canada (PO, twice-daily dosing)